NCT03856099 - TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2019

Primary Completion Date

July 15, 2022

Study Completion Date

July 15, 2022

Conditions

Recurrent Glioblastoma

Interventions

DRUG

TTAC-0001

"* Investigational product (IP): TTAC-0001~* Treatment groups: 3 dose groups~ * Dose group A : TTAC-0001 16 mg/kg on D1 and D15~ * Dose group B : TTAC-0001 20 mg/kg on D1 and D15~ * Dose group C : TTAC-0001 24 mg/kg on D1 and D15~* Cycle: 4 weeks (28 days per cycle)"

Trial Locations (3)

3084

Austin Hospital, Heidelberg

32804

Florida Hospital Cancer Institute & Florida Hospital Orlando, Orlando

94305

Stanford Avanced Medical Center, Stanford